Literature DB >> 2806301

Arrhythmogenic right and left ventricular disease: evaluation by computed tomography and nuclear magnetic resonance imaging.

C Klersy1, A Raisaro, J A Salerno, C Montemartini, R Campani.   

Abstract

Ventricular tachycardia may represent the first sign of an unknown cardiomyopathy; fewer data are available on the anatomical substrate of the arrhythmia. The aim of the study was to characterize better those patients who usually do not have haemodynamic impairment, but in whom the arrhythmia may be severely invalidating. To that purpose, two recent and sophisticated radiological methods were used, computed tomography (CT) and nuclear magnetic resonance (NMR); both methods allowed a precise characterization of the morphology and function of the right and left ventricle; a tissue analysis was performed that identified regions of lipomatous degeneration both in the right and the left ventricle, particularly with NMR. In conclusion, CT and particularly NMR appear to be able to reveal minimal changes suggestive of a right and/or left cardiomyopathy whose first manifestation is ventricular tachycardias.

Entities:  

Mesh:

Year:  1989        PMID: 2806301     DOI: 10.1093/eurheartj/10.suppl_d.33

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  3 in total

Review 1.  Localization of cardiac arrhythmias: conventional noninvasive methods.

Authors:  S Yuan; P Blomström; S Pehrson; S B Olsson
Journal:  Int J Card Imaging       Date:  1991

2.  Spin-echo nuclear magnetic resonance for tissue characterisation in arrhythmogenic right ventricular cardiomyopathy.

Authors:  L Menghetti; C Basso; A Nava; A Angelini; G Thiene
Journal:  Heart       Date:  1996-12       Impact factor: 5.994

3.  Value of the echocardiographic findings of arrhythmogenic right ventricular dysplasia with left ventricular involvement in a child.

Authors:  S Atalay; A Imamoglu; H Gümüs; M Gürdal; M Ozenci
Journal:  Pediatr Cardiol       Date:  1996 Jan-Feb       Impact factor: 1.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.